Fractyl Health, Inc.
Fractyl Health, Inc. (Nasdaq: GUTS) is a clinical-stage metabolic therapeutics company developing treatments for obesity and type 2 diabetes. Its lead candidate, Revita, is an investigational outpatient endoscopic procedure that uses hydrothermal ablation to remodel the duodenal lining; the company is studying its… From the company’s description.
In fiscal 2025, Fractyl Health, Inc. reported a net loss of $140.95M. Operations used $90.33M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Fractyl Health, Inc. does
In the company’s own words
Fractyl Health, Inc. (Nasdaq: GUTS) is a clinical-stage metabolic therapeutics company developing treatments for obesity and type 2 diabetes. Its lead candidate, Revita, is an investigational outpatient endoscopic procedure that uses hydrothermal ablation to remodel the duodenal lining; the company is studying its potential to help people maintain weight loss after stopping GLP-1-based therapy. Fractyl has evaluated Revita in more than 500 participants across clinical studies in the United States, Europe and South America. Its Rejuva platform comprises locally administered pancreatic gene therapies designed to prompt islet cells to produce metabolic hormones. The lead candidate, RJVA-001, is designed to enable pancreatic beta cells to produce GLP-1, while RJVA-002, in preclinical development, is designed to produce both GIP and GLP-1. These candidates are intended to address type 2 diabetes and obesity, respectively, through a single intervention. The company’s principal programs are Revita and Rejuva; it has no commercial products described.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- BURLINGTON, MA
- Fiscal year end
- December
- CIK
- 1572616
- SIC
- 3841
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Fractyl Health, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Fractyl Health, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Fractyl Health, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Fractyl Health, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Fractyl Health, Inc.'s last four quarterly filings that the numbers alone won't show?”